BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2

In classical hairy cell leukemia (HCL), standard treatments including purine analogs achieve a durable response (up to 90%), but lead to severe immunosuppression and long-lasting depletion of CD4 + T lymphocytes. The BRAF inhibitor vemurafenib is effective in HCL, but its use in first-line treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Konrat, Judith, Rösler, Wiebke, Roiss, Michael, Meier-Abt, Fabienne, Widmer, Corinne C., Balabanov, Stefan, Manz, Markus G., Zenz, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735012/
https://www.ncbi.nlm.nih.gov/pubmed/36494600
http://dx.doi.org/10.1007/s00277-022-05026-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735012/
https://www.ncbi.nlm.nih.gov/pubmed/36494600
http://dx.doi.org/10.1007/s00277-022-05026-z

Ejemplares similares